Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol - NCT00682916-95817 (Clinical Trial 222520)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy222520.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Sacramento |
|
State:
|
|
CA |
| Zip Code: |
|
95817 |
| Conditions: |
|
Obesity |
| Purpose: |
|
Obesity and type 2 diabetes have clearly been linked together and identified as epidemics in
much of the developed world. Historically several different dietary fibers have been used
as means of reducing body weight and the related development of type 2 diabetes. These
studies have generated mixed, if not inconsistent, results suggesting that none of these
fibers promise a solution to either of these two conditions. We are proposing to
investigate the effects of including a new soluble fiber, a-cyclodextrin, FBCx® (to be
called Y288 in this study), into the diet of adult overweight volunteers.
|
| Study summary: |
|
The overall aim is to investigate the effectiveness of a soluble dietary fiber, FBCx®, on
weight loss and/or weight management, and blood lipid levels in overweight humans. |
| Criteria: |
|
Inclusion Criteria:
- 30 men and 30 women
- Age 18- 65 years
- BMI 25.0 - 32.0 Kg/m²
- fasting glucose <126 mg/dL
- Blood pressure < 140/85 mm Hg. Hypertension on stable drug regimen using 2 or fewer
antihypertensives will be acceptable.
- Total plasma cholesterol <240 mg/dl, LDL-cholesterol <160 and triglycerides <400
mg/dl. Hyperlipidemia on a stable medication regimen using single
anti-hyperlipidemic drug acceptable.
Exclusion Criteria:
- Pregnant women, women who plan to become pregnant during the study period
- Women who have given birth within the previous 12 months
- Lactating women
- History or presence of Type 2 diabetes; kidney disease; (creatinine >1.4); liver
disease (X2 fold increase in AST or ALT); gout; cancer; untreated thyroid disease;
gastrointestinal disease; other metabolic diseases or malabsorption syndromes
- Habitual low-fat intake (less than 20%)
- History of eating disorder
- Subjects who have lost 10% of body weight within the last 12 months or who plan to
initiate a weight loss program
- Use of prescription or over-the counter anti-obesity medications or supplements
(phenylpropanolamine, ephedrine, caffeine) for at least 6 months prior of study.
- Subjects with pacemakers will not participate in bioimpedance studies but will go
through all the other testing. |
|
|
|
| Study is available at: |
|
UC Davis
Sacramento, CA 95817
United States
Primary Contact:
Melinda Posas, BS
Email: velayo.melinda@gmail.com
Phone: 916-734-4777
Secondary Contact:
Melinda Posas, BS
Email: velayo.melinda@gmail.com
Phone: 916-734-4747 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 16, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|